Literature DB >> 7995185

Amino acid derivatives of 5-ASA as novel prodrugs for intestinal drug delivery.

C Clerici1, G Gentili, E Boschetti, C Santucci, A G Aburbeh, B Natalini, R Pellicciari, A Morelli.   

Abstract

In an attempt to obtain site-specific delivery of 5-ASA in the intestinal tract, we have determined the extent of absorption and metabolism of a number of novel 5-ASA derivatives, namely, (N-L-glutamyl)-amino-2-salicylic acid (1), (N-L-aspartyl)-amino-2-salicylic-acid (2), 5-aminosalicyl-L-proline-L-leucine (3), and 5-(N-L-glutamyl)-aminosalicyl-L-proline-L-leucine (4), which are selectively cleaved by intestinal brush border aminopeptidase A and carboxypeptidases. These novel prodrugs, 5-ASA, and sulfasalazine were administered to adult Fisher rats (N = 30) and to animals that had undergone prior colostomy (N = 30). Urine and feces were collected at timed intervals for 48 hr and the metabolites, 5-ASA, and N-acetyl-5-ASA were measured by high-performance liquid chromatography. The absorption and metabolism of all compounds were essentially identical in colostomized and normal animals. 5-ASA exhibited a rapid proximal intestinal absorption as evidenced by the high cumulative urinary excretion (> 65%) and low fecal excretion. Sulfasalazine, as expected, exhibited a lower urinary recovery (< 35%) and higher fecal excretion of 5-ASA and its metabolite. The novel glutamate and aspartate derivatives (1 and 2) behaved similarly to sulfasalazine, while administration of the proline-leucine derivative (3) resulted in urinary and fecal recovery values intermediate with respect to those observed with 5-ASA and sulfasalazine. 5-(N-L-Glutamyl)-aminosalicyl-L-proline-L-leucine yielded the highest fecal recovery of 5-ASA and its N-acetyl derivative, indicating a more efficient delivery to the distal bowel. Amino acid derivatives of 5-ASA appear to be potentially useful prodrugs for the site-specific delivery of 5-ASA to different regions of the intestinal tract.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7995185     DOI: 10.1007/BF02087696

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.

Authors:  J H BARON; A M CONNELL; J E LENNARD-JONES; F A JONES
Journal:  Lancet       Date:  1962-05-26       Impact factor: 79.321

2.  Salicylazosulfapyridine in inflammatory bowel disease.

Authors:  K M Das; I Sternlieb
Journal:  Am J Dig Dis       Date:  1975-10

3.  Dipeptidylaminopeptidase and carboxypeptidase activities of the brush border of rabbit small intestine.

Authors:  S Auricchio; L Greco; B de Vizia; V Buonocore
Journal:  Gastroenterology       Date:  1978-12       Impact factor: 22.682

4.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  N Engl J Med       Date:  1973-09-06       Impact factor: 91.245

5.  Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.

Authors:  L Staerk Laursen; M Stokholm; K Bukhave; J Rask-Madsen; K Lauritsen
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

Review 6.  Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.

Authors:  A N Wadworth; A Fitton
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

7.  A simple and rapid liquid chromatographic method for the determination of major metabolites of sulfasalazine in biological fluids.

Authors:  V S Chungi; G S Rekhi; L Shargel
Journal:  J Pharm Sci       Date:  1989-03       Impact factor: 3.534

Review 8.  Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development.

Authors:  M A Peppercorn
Journal:  Ann Intern Med       Date:  1984-09       Impact factor: 25.391

9.  Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide.

Authors:  R P Chan; D J Pope; A P Gilbert; P J Sacra; J H Baron; J E Lennard-Jones
Journal:  Dig Dis Sci       Date:  1983-07       Impact factor: 3.199

10.  The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  Gut       Date:  1973-08       Impact factor: 23.059

View more
  1 in total

1.  In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery.

Authors:  C S Leopold; D R Friend
Journal:  J Pharmacokinet Biopharm       Date:  1995-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.